Southwest Oncology Group: Two decades of experience in non-small cell lung cancer

Andrew T. Turrisi, John Crowley, Kathy Albain, Laurie Gaspar, David R Gandara

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume32
Issue numberSUPPL. 3
DOIs
StatePublished - Apr 2005

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Southwest Oncology Group: Two decades of experience in non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this